Neuro-oncology: a selected review of ASCO 2011 abstracts

References

• Ewend MG, Meyers CA, Silva E, Booth-Jones M, Jain S, Brem S. Effects of surgery with BCNU wafer placement on neurocognitive function in patients with one to three brain metastases. J. Clin. Oncol.29(15 Suppl., part I of II), 143s (2011) (Abstract 2015).
   Google Scholar
• Brem S, Sampath R, Yu D, Staller A, Obadia M, Ewend MG. Stereotactic volumetric resection, intracavitary carmustine wafers, and radiation therapy for brain metastases: the Moffitt Cancer Center experience. J. Clin. Oncol.29(15 Suppl., part I of II), 159s (2011) (Abstract 2077).
   Google Scholar
• Welsh J, Amini A, Kim ES et al. Phase II study of erlotinib with concurrent whole-brain radiation therapy for patients with brain metastases from non-small lung cancer. J. Clin. Oncol.29(15 Suppl., part I of II), 147s (2011) (Abstract 2031).
   Google Scholar
• Salinque S, Griot M, Rodrigues S et al. Value of CA 15-3 detection in cerebrospinal fluid (CSF) of breast cancer leptomeningeal metastases. J. Clin. Oncol.29(15 Suppl., part I of II), 158s (2011) (Abstract 2075).
   Google Scholar
• Weston CL, Zalatimo O, Sheehan J et al. Novel use of MR spectroscopy in detecting CSF lactate for diagnosis of neoplastic meningitis. J. Clin. Oncol.29(15 Suppl., part I of II), 157s (2011) (Abstract 2071).
   PubMedGoogle Scholar
• Zoccoli CM, Zalatimo O, Glantz MJ. Is cerebrospinal fluid cytology a useful test? J. Clin. Oncol.29(15 Suppl., part I of II), 159s (2011) (Abstract 2079).
   Google Scholar
• Chamberlain MC, Johnston SK. Neurotoxicity of intra-CSF liposomal cytarabine in the treatment of leptomeningeal metastases. J. Clin. Oncol.29(15 Suppl., part I of II), 155s (2011) (Abstract 2062).
   Google Scholar
• Le Rhun E, Kotecki N, Zairi F et al. Prospective follow-up of 96 patients with breast cancer with leptomeningeal metastasis recruited from 2007 to 2010. J. Clin. Oncol.29(15 Suppl., part I of II), 162s (2011) (Abstract 2089).
   Google Scholar
• Norden AD, Hammond S, Drappatz J et al. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. J. Clin. Oncol.29(15 Suppl., part I of II), 150s (2011) (Abstract 2040).
   Google Scholar
• Grimm SA, Chamberlain MC, Chandler J et al. A Phase II trial PTK787/ZK 222584 (PTK787) in recurrent high-grade meningioma. J. Clin Oncol.29(15 Suppl., part I of II), 151s (2011) (Abstract 2046).
   Google Scholar
• Dhall G, Ji L, Haley K et al. Outcome of infants and young children with newly diagnosed medulloblastoma treated on Head Start III protocol. J. Clin. Oncol.29(15 Suppl., part I of II), 142s (2011) (Abstract 2011).
   PubMedGoogle Scholar
• Dagri JN, Evans A, Torkildson J et al. Feasibility pilot of attenuated maintenance chemotherapy for adolescents and adults with newly diagnosed localized medulloblastoma and other primitive neuroectodermal tumors. J. Clin. Oncol.29(15 Suppl., part I of II), 160s (2011) (Abstract 2081).
   Google Scholar
• Koschmann C, Schmidt KL, Geyer JR, Leary S. Survival after recurrence of medulloblastoma in the contemporary era. J. Clin Oncol.29(15 Suppl., part I of II), 157s (2011) (Abstract 2068).
   PubMedGoogle Scholar
• Jahnke K, Korfel A, Martus P et al. Prognostic factors for response and survival in primary central nervous system lymphoma (PCNSL) from a randomized Phase III trial (G-PCNSL-SG1). J. Clin. Oncol.29(15 Suppl., part I of II), 141s (2011) (Abstract 2004).
   Google Scholar
• Abrey LE, Ben-Porat L, Panageas KS et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J. Clin. Oncol.24(36), 5711–5715 (2006).
   PubMed Web of Science ®Google Scholar
• Martus P, Jahnke K, Korfel A et al. Prognostic factors for chemotherapy-related toxicity in primary central nervous system lymphoma (PCNSL) treated with high-dose methotrexate (HDMTX) with or without ifosfamide: results from a German Phase III trial (G-PCNSL-SG-1). J. Clin. Oncol.29(15 Suppl., part I of II), 141s (2011) (Abstract 2005).
   Google Scholar
• Korfel A, Fischer L, Martus P et al. Impact of meningeal dissemination (MD) on outcome in primary CNS lymphoma in the G-PCNSL-SG1 trial. J. Clin. Oncol.29(15 Suppl., part I of II), 146s (2011) (Abstract 2026).
   Google Scholar
• Thiel E, Korfel A, Martus P et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a Phase 3, randomized non-inferiority trial. Lancet Oncology11(11), 1036–1047 (2010).
   PubMed Web of Science ®Google Scholar
• Pentsova E, DeAngelis LM, Omuro AM. Methotrexate (MTX) rechallenge for recurrent primary CNS lymphoma (PCNSL). J. Clin. Oncol.29(15 Suppl., part I of II), 146s (2011) (Abstract 2025).
   Google Scholar
• Nayak L, Abrey LE, Drappatz J et al. Multicenter Phase II trial of temozolomide (TMZ) and rituximab (RIT) for recurrent primary CNS lymphoma (PCNSL): North American Brain Tumor Consortium (NABTC) study 05–01. J. Clin. Oncol.29(15 Suppl., part I of II), 149s (2011) (Abstract 2039).
   PubMedGoogle Scholar
• Chinot OL, Hoang-Xuan K, Fabbro M et al. TEMOBIC: a ANOCEF Phase II study of BCNU and temozolomide (TMZ) combination prior to radiotherapy (RT) in anaplastic oligodengroglial gliomas (AOG). J. Clin. Oncol.29(15 Suppl., part I of II), 148s (2011) (Abstract 2034).
   Google Scholar
• Satra A, Hashemi-Sadraei N, Bawa HS et al. Prognostic factors in elderly patients with grade 3 gliomas. J. Clin. Oncol.29(15 Suppl., part I of II), 163s (2011) (Abstract 2093).
   Google Scholar
• Metellus P, Coulibaly B, Colin C et al. Triple negative, low grade gliomas: a highly aggressive tumor with dismal prognosis. J. Clin. Oncol.29(15 Suppl., part I of II), 145s (2011) (Abstract 2023).
   Google Scholar
• Gilbert MR, Wang M, Aldape KD et al. RTOG 0525: a randomized Phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM). J. Clin. Oncol.29(15 Suppl., part I of II), 141s (2011) (Abstract 2006).
   Google Scholar
• Bach F, Westphal M; OSAG-101 Study Group. Current status of a Phase III trial of nimotuzumab (ti-EGF-R) in newly diagnosed glioblastoma. J. Clin. Oncol.29(15 Suppl., part I of II), 154s (2011) (Abstract 2059).
   Google Scholar
• Chinot OL, Wick W, Saran F et al. AVAglio: a Phase III trial of bevacizumab added to standard radiotherapy and temozolomide in patients with newly diagnosed glioblastoma. J. Clin. Oncol.29(15 Suppl., part I of II), 16s (2011) (Abstract TPS136).
   Google Scholar
• Verschaeve V, D’Hondt LA, Verbeke LM et al. CeCil: a randomized, noncomparative Phase II clinical trial of the effect of radiation therapy (RT) plus temozolomide (TMZ) combined with cilengitide or cetuximab on the 1-year overall survival of patients with newly diagnosed MGMT-promoter unmethylated glioblastoma. J. Clin. Oncol.29(15 Suppl., part I of II), 15s (2011) (Abstract TPS134).
   Google Scholar
• Chauffert B, Feuvret L, Bonnetain F et al. Randomized multicenter Phase II trial of irinotecan and bevacizumab as neoadjuvant and adjuvant to temozolomide-based chemoradiation versus chemoradiation for unresectable glioblastoma: interim results of the TEMAVIR study from ANOCEF group. J. Clin. Oncol.29(15 Suppl., part I of II), 147s (2011) (Abstract 2029).
   Google Scholar
• Hofland KF, Hansen S, Sorensen M et al. Randomized Phase II study of neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoreaadiotherapy in newly diagnosed primary glioblastoma multiforme. J. Clin. Oncol.29(15 Suppl., part I of II), 153s (2011) (Abstract 2052).
   Google Scholar
• Wick W, Steinbach J, Combs SE et al. Enzastaurin (ENZ) before and concomitant with radiation therapy (RTX) followed by ENZ maintenance therapy in patients with newly diagnosed glioblastoma (GBM) without hypermethylation of the O6-methylguanyl DNA-methyltransferase (MGMT) promoter: a multicenter, open-label, uncontrolled Phase II study. J. Clin. Oncol.29(15 Suppl., part I of II), 141s (2011) (Abstract 2007).
   Google Scholar
• Khasraw M, McCowatt S, Kerestes Z, Buyse ME, Back M, Wheeler H. Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB, and the integrin inhibitor cilengitide in patients with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric). J. Clin. Oncol.29(15 Suppl., part I of II), 15s (2011) (Abstract TPS133).
   Google Scholar
• Omuro AMP, Beal K, Karimi S et al. Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM). J. Clin. Oncol.29(15 Suppl., part I of II), 147s (2011) (Abstract 2028).
   Google Scholar
• Lou E, Reardon DA, Peters K et al. Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma. J. Clin. Oncol.29(15 Suppl., part I of II), 153s (2011) (Abstract 2055).
   Google Scholar
• Quant EC, Batchelor T, Lassman AB et al. Preliminary results from a multicenter, phase II, randomized, noncomparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma (GBM). J. Clin. Oncol.29(15 Suppl., part I of II), 157s (2011) (Abstract 2069).
   PubMedGoogle Scholar
• Beauchesnes PD, Faure G, Noel G et al. Concurrent, 3-times daily ultrafractionated radiation therapy and temozolomide for newly inoperable glioblastoma: TEMOFRAC a Phase II trial. J. Clin. Oncol.29(15 Suppl., part I of II), 158s (2011) (Abstract 2073).
   Google Scholar
• Vredenburgh JJ, Desjardins A, Reardon DA et al. Bevacizumab, temozolomide, and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly-diagnosed glioblastoma multiforme (GBM). J. Clin. Oncol.29(15 Suppl., part I of II), 164s (2011) (Abstract 2098).
   Google Scholar
• Jeyapalan SA, Goldmann M, Donahur J et al. A Phase II study of paclitaxel poliglumex (PPX), temozolomide (TMX), and radiation (RT) for newly diagnosed high-grade gliomas. J. Clin. Oncol.29(15 Suppl., part I of II), 149s (2011) (Abstract 2036).
   PubMedGoogle Scholar
• Phuphanich S, Wheeler CJ, Rudnick J et al. Glioma-associated antigens associated with prolonged survival in a Phase I study of ICT-107 for patients with newly diagnosed glioblastoma. J. Clin. Oncol.29(15 Suppl., part I of II), 150s (2011) (Abstract 2042).
   Google Scholar
• DeGroot JF, Cloughesy T, Lieberman FS et al. Phase I study of aflibercept (VEGF Trap) and temozolomide in newly diagnosed, high-grade glioma. J. Clin. Oncol.29(15 Suppl., part I of II), 150s (2011) (Abstract 2043).
   Google Scholar
• Wen PY, Puduvalli VK, Kuhn JG et al. Phase I study of vorinostat in combination with temozolomide in patients with malignant gliomas. J. Clin. Oncol.29(15 Suppl., part I of II), 148s (2011) (Abstract 2032).
   Google Scholar
• Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med.352(10), 997–1003 (2005).
   PubMed Web of Science ®Google Scholar
• Lwin Z, MacFadden D, AL-Zahrani A et al. A population-based study of glioblastom multiforme (GBM) in the new stupp paradigm: have we improved outcome? J. Clin. Oncol.29(15 Suppl., part I of II), 143s (2011) (Abstract 2012).
   Google Scholar
• Koshy M, Villano JL, Dolecek TA et al. Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J. Clin. Oncol.29(15 Suppl., part I of II), 143s (2011) (Abstract 2013).
   Google Scholar
• Preusser M, Woehrer MA, Zielonke N et al. Real-life survival in unselected adult glioblastoma patients: a population-based study. J. Clin. Oncol.29(15 Suppl., part I of II), 143s (2011) (Abstract 2014).
   Google Scholar
• Eisenstat DD, Nabors LB, Mason WP et al. A Phase II study of daily afatinib (BIBW 2992) with or without temozolomide (21/28 days) in the treatment of patients with recurrent glioblastoma. J. Clin. Oncol.29(15 Suppl., part I of II), 142s (2011) (Abstract 2010).
   PubMedGoogle Scholar
• Soffietti R, Trevisan E, Ruda R et al. Phase II trial of bevacizumab with fotemustine in recurrent glioblastoma: final results of a multicenter study of AINO (Italian Association of Neuro-oncology). J. Clin. Oncol.29(15 Suppl., part I of II), 146s (2011) (Abstract 2027).
   Google Scholar
• Reardon DA, Vredenburgh JJ, Desjardins A et al. Bevacizumab (BV) continuation following BV progression: meta-analysis of five consecutive recurrent glioblastoma (GBM) trials. J. Clin. Oncol.29(15 Suppl., part I of II), 147s (2011) (Abstract 2030).
   Google Scholar
• Jaeckle KA, Schiff D, Anderson SK et al. NCCTG N0572 Phase I/II trial of sorafenib and temsirolimus in patients with recurrent glioblastoma: a North Central Cancer Treatment Group study. J. Clin. Oncol.29(15 Suppl., part I of II), 148s (2011) (Abstract 2033).
   Google Scholar
• Hammond S, Norden AD, Lesser GJ et al. Phase II study of dose-intense temozolomide in recurrent glioblastoma: Phase II study of dose-intense temozolomide in recurrent glioblastoma. J. Clin. Oncol.29(15 Suppl., part I of II), 149s (2011) (Abstract 2038).
   PubMedGoogle Scholar
• Bota DA, Erogluz, Reardon DA et al. Phase II clinical trial of bortezomib and bevacizumab combination in recurrent glioblastoma. J. Clin. Oncol.29(15 Suppl., part I of II), 154s (2011) (Abstract 2056).
   Google Scholar
• Paccepelo ALolli I, Scocciantis et al. Efficacy of nitrosourea-based chemotherapy in recurrent malignant glioma according to time to adjuvant temozolomide failure: a pooled analysis. J. Clin. Oncol.29(15 Suppl., part I of II), 155s (2011) (Abstract 2060).
   Google Scholar
• Zustovich F, Landi L, Lombaardi G et al. Sorafenib plus daily low dose temozolomide for relapsed glioblastoma: a Phase II study. J. Clin. Oncol.29(15 Suppl., part I of II), 160s (2011) (Abstract 2080).
   Google Scholar
• Cuneo KC, Cabrera AR, Sampson JH et al. Safety results from prospective study of concurrent radiosurgery and bevacizumab for recurrent malignant glioma. J. Clin. Oncol.29(15 Suppl., part I of II), 160s (2011) (Abstract 2082).
   Google Scholar
• Kim LJ, Chamberlain MC, Zhu J et al. Phase II study of verubulin (MPC-6827) for the treatment of subjects with recurrent glioblastoma naive to treatment with bevacizumab. J. Clin. Oncol.29(15 Suppl., part I of II), 162s (2011) (Abstract 2088).
   Google Scholar
• Drappatz J, Raizer JJ, Schiff D et al. A Phase I trial of LBH589 and bevacizumab for recurrent high-grade glioma (HGG). J. Clin. Oncol.29(15 Suppl., part I of II), 152s (2011) (Abstract 2050).
   Google Scholar
• Raizer JJ, Rice L, Rademaker A et al. A Phase I trial of laromustine (VPN40101M) and temozolomide for patients with malignant gliomas in first relapse of progression. J. Clin. Oncol.29(15 Suppl., part I of II), 156s (2011) (Abstract 2064).
   Google Scholar
• Perry JR, Mason WP, Belanger K et al. The temozolomide RESCUE study: a Phase II trial of continuous (28/28) dose-intense temozolomide (TMZ) after progression on conventional 5/28 day TMZ in patients with recurrent malignant glioma. J. Clin. Oncol.26(15 Suppl.), (2010) (Abstract 2008).
   Google Scholar
• Gutin PH, Iwamoto FM, Beal K et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int. J. Radiat. Oncol. Biol. Phys.75(1), 156–63 (2009).
   PubMedGoogle Scholar
• Batchelor T, Mulholland P, Neyns B et al. A Phase III randomized study comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, with lomustine alone in recurrent glioblastoma patients. Neuro Oncol.12(Suppl 4), iv69 (2010) (Abstract OT-25).
   Google Scholar
• Aldape KD, Wang M, Sulman EP et al. RTOG 0525: Molecular correlates from a randomized Phase III trial of newly diagnosed glioblastoma. J. Clin. Oncol.29(18S, part II of II), 779s (2011) (Abstract LBA2000).
   Google Scholar
• Weller M, Hentschel B, Felsberg J et al. Impact of MGMT promoter methylation in glioblastoma of the elderly. J. Clin. Oncol.29(15 Suppl., part I of II), 140s (2011) (Abstract 2001).
   Google Scholar
• Frenel J, Leux C, Loussouarn D et al. Predictive value of IDH1 mutation assessed by immunohistochemistry and DNA sequencing in WHO grade 3 oligodendrogliomas. J. Clin. Oncol.29(15 Suppl., part I of II), 140s (2011) (Abstract 2002).
   Google Scholar
• Lai A, Lalezari S, Chou AP et al. Prediction of GBM outcome using combined analysis of MGMT protein expression and promoter methylation. J. Clin. Oncol.29(15 Suppl., part I of II), 140s (2011) (Abstract 2003).
   Google Scholar
• Bertolini F, Baraldi C, Zunarelli E et al. O(6)-methylguanine DNA-methyltransferase (MGMT) in glioblastoma: analysis on first and following surgeries. J. Clin. Oncol.29(15 Suppl., part I of II), 163s (2011) (Abstract 2097).
   Google Scholar